BANDUNG - Director General of Disease Prevention and Control (P2P) of the Indonesian Ministry of Health, Anung Sugihantono together with Sri Harsi Teteki, Marketing Director of Bio Farma, Prof. Soedjatmiko from the Immunization Task Force, Dr. Toto from Komnas KIPI, as well as representatives from the Community of Immunization Care and parents of Rubella patients attended the media meeting in Jakarta.
According to Anung Sugihantono, Director General of P2P Ministry of Health, "MR immunization will begin simultaneously on August 1 to September 2018 for infants aged 9 months to 15 years old children."
"The targets that immunized as much as 31,963,154 in 28 provinces outside Java. 2017 has been implemented in 6 provinces in Java (West Java, East Java, Central Java, DKI Jakarta, Banten, DIY)," said Agung.
The Ministry of Health Republic Indonesia, has a commitment to achieve the elimination of measles and control of rubella and congenital rubella syndrome (CRS) by 2020. This commitment will be realized through the additional vaccination of Measles Rubella (MR) for infants aged 9 months - children under 15 years of age.
In 2018, the government will launch the MR Stage 2 vaccine program to be held in South Sulawesi Province, and will be followed by other provinces outside of Java. As for the provinces on the island of Java, it has already been implemented in the first stage of the 2017 MR vaccine in Yogyakarta.
Sri Harsi Teteki, Marketing Director of Bio Farma stated ready with MR Vaccine supply and sufficient according to Kemenkes immunization target.
"Currently there are only 2 MR vaccine manufacturers, there are in China and India, but those that have complete requirements only from India. All MR vaccines used for the MR Campaign in stage 1 and stage 2 are from Bio Farma's partners in India, its MR vaccine production has been used in 140 countries, including Islamic countries that have already launched this vaccine, aand have been through security studies in various countries in the world, "Sri added.
Sri added, "Bio Farma is very concerned with halal issues, as regulated by halal certification registration must be done by manufacturer or vaccine manufacturer, in this case, the factory in India".
In November 2017 Bio Farma Team visited the MR vaccine manufacturer in India, and said that halal certification is required by the Government of Indonesia. His party continues to consult, coordinate and assist MR vaccine producers and communicate with the MUI fatwa commission for this certification process.
Bambang Heriyanto, Corporate Secretary added, "Currently Bio Farma is already independent for Vaccine Measles (measles), we are currently developing for Measles & Rubella (MR) combination vaccines with Bulk Rubella in collaboration with other parties, MR vaccine research targets in 2020, we expect the target of 2024 MR vaccine for Bio Farma products to be ready ".
"It takes a long time to produce vaccine, we need to be careful for vaccine production process to be free from animal aspect, besides paying attention to quality aspect, safety and product efficacy," Bambang concluded. (Pun)